Cancer stem cells in ovarian cancer

Česká verzia

Authors: Alena Ürgeová ¹; Pavel Pitule ^2,3; Miroslava Čedíková ²; Jiří Bouda ¹
Authors place of work: Gynekologicko – porodnická klinika LF UK a FN Plzeň ¹; Ústav histologie a embryologie LF UK, Plzeň ²; Chirurgická klinika LF UK a FN Plzeň ³
Published in the journal: Prakt Gyn 2012; 16(1): 42-44
Category: Oncogynecology: Case report

Summary

Objective:
Analysis of current knowledge of cancer stem cells subpopulation in ovarian cancer.

Design:
Review article

Methods:
The review of literature about cancer stem cells in ovarian cancer.

Conclusion:
The cancer stem cells (CSCs) hypothesis is becoming more widely accepted as a model for carcinogenesis. It is assumed that cancer stem cells research could provide novel target therapeutics.

Key words:
cancer stem cells –ovarian cancer

Zdroje

1. Alison MR, Lin SM, Nicholson LJ. Cancer stem cell: problems for therapy? J Pathol 2011; 223(2): 147–161.

2. Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010; 138(6): 2151–262.

3. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic dinase. J Cell Mol Med 2008; 12(2): 374–390.

4. Bao S, Wu Q, McLendon RE. Glioma stem cells promote radioresistance by preferential activation of the DNA, damage response. Nature 2006; 444(7120): 756–760.

5. Dick JE, Bhatia M, Gan O, Kapp U. Assay of human, stem cells by repopulation of NOD/SCID mice. Stem Cells 1997; 15(1): 199–207.

6. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008; 456(7222): 593–598.

7. Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patiens with solid tumors. Cancer Treat Rev 2008; 34(1): 37–48.

8. Baba T, Convery PA, Matsumura N et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28(2): 209–218.

9. Curley MD, Therrien VA, Cummings CL et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27(12): 2875–2883.

10. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage clear-cell epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006; 102(2): 285–291.

11. Weng D, Song B, Durfee J et al. Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. Int J Cancer 2011; 129(8): 1990–2001.

12. Steffensen KD, Alvero AB, Yang Y et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol 2011; 2011: 620523.

13. Ween MP, Oehler MK, Ricciardelli C. Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis. Int J Mol Sci2011; 12(2): 1009–1029.

14. Luo L, Zeng J, Liang B et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 2011; 91(2): 596–602.

15. Masopust J. Kmenové buňky a vznik nádorového onemocnění. Tumorigeneze jako onemocnění kmenových buněk. Labor Aktuell 2008; 1. Dostupné z: <http://www.roche-diagnostics.cz/casopisy/la/2008.aspx>